Cencora, Inc. (COR) Insider Trading Activity

NYSE$350.52+10.02 (2.94%)
Market Cap
$64.98B
Sector
Healthcare
Industry
Medical—Distribution
Rank in Sector
91 of 849
Rank in Industry
1 of 7

COR Insider Trading Activity

COR Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$2,310,427
3
19
Sells
$15,384,608
13
81

Related Transactions

DURCAN DERMOT MARKdirector
2
$2.16M
0
$0
$2.16M
Tyler Lauren Mdirector
1
$148,627
0
$0
$148,627
GREENBERG LON Rdirector
0
$0
1
$411,264
$-411,264
Battaglia SilvanaExecutive Vice President
0
$0
1
$578,565
$-578,565
Krikorian LazarusSVP & Chief Accounting Officer
0
$0
4
$2.33M
$-2.33M
Campbell Elizabeth SExecutive Vice President
0
$0
2
$4.81M
$-4.81M
Mauch Robert P.President & CEO
0
$0
5
$7.26M
$-7.26M

About Cencora, Inc.

Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, …

Insider Activity of Cencora, Inc.

Over the last 12 months, insiders at Cencora, Inc. have bought $2.31M and sold $15.38M worth of Cencora, Inc. stock.

On average, over the past 5 years, insiders at Cencora, Inc. have bought $1.21M and sold $728.36M worth of stock each year.

Highest buying activity among insiders over the last 12 months: DURCAN DERMOT MARK (director) — $2.16M. Tyler Lauren M (director) — $148,627.

The last purchase of 550 shares for transaction amount of $148,627 was made by Tyler Lauren M (director) on 2026‑06‑22.

List of Insider Buy and Sell Transactions, Cencora, Inc.

2026-11-02SaleKrikorian LazarusSVP & Chief Accounting Officer
986
0.0005%
$330.96
$326,327
+2.88%
2026-10-01SaleKrikorian LazarusSVP & Chief Accounting Officer
986
0.0005%
$303.18
$298,935
+6.70%
2026-09-16SaleGREENBERG LON Rdirector
1,280
0.0007%
$321.30
$411,264
+1.76%
2026-09-01SaleKrikorian LazarusSVP & Chief Accounting Officer
985
0.0005%
$325.97
$321,080
-2.08%
2026-08-24SaleCampbell Elizabeth SExecutive Vice President
11,300.47
0.0059%
$324.12
$3.66M
+0.10%
2026-06-22PurchaseTyler Lauren Mdirector
550
0.0003%
$270.23
$148,627
+16.87%
2026-06-18PurchaseDURCAN DERMOT MARKdirector
4,000
0.0021%
$274.19
$1.1M
+16.61%
2026-05-28PurchaseDURCAN DERMOT MARKdirector
4,000
0.0021%
$266.26
$1.07M
+16.92%
2026-02-20SaleMauch Robert P.President & CEO
3,762
0.0019%
$358.94
$1.35M
-12.55%
2026-02-18SaleMauch Robert P.President & CEO
1,333
0.0007%
$359.46
$479,160
-12.27%
2026-01-20SaleMauch Robert P.President & CEO
5,096
0.0027%
$354.73
$1.81M
-8.99%
2025-12-19SaleCampbell Elizabeth SExecutive Vice President
3,351
0.0017%
$342.10
$1.15M
-5.71%
2025-12-19SaleBattaglia SilvanaExecutive Vice President
1,677
0.0009%
$345.00
$578,565
-5.71%
2025-12-18SaleMauch Robert P.President & CEO
5,096
0.0027%
$343.45
$1.75M
-5.60%
2025-12-17SaleKrikorian LazarusSVP & Chief Accounting Officer
4,031
0.0021%
$343.24
$1.38M
-6.22%
2025-11-18SaleMauch Robert P.President & CEO
5,096
0.0027%
$366.64
$1.87M
-10.07%
2025-10-20SaleMauch Robert P.President & CEO
5,097
0.0026%
$326.80
$1.67M
-0.35%
2025-10-01SaleCampbell Elizabeth SExecutive Vice President
1,886
0.001%
$313.28
$590,846
+4.14%
2025-09-18SaleMauch Robert P.President & CEO
5,097
0.0026%
$290.00
$1.48M
+11.64%
2025-09-16SaleCOLLIS STEVEN HExecutive Chairman
31,350
0.0162%
$289.86
$9.09M
+11.96%
Total: 207
*Gray background shows transactions not older than one year

Insider Historical Profitability

4.69%
DURCAN DERMOT MARKdirector
31767
0.0166%
$10.82M30
+9.56%
Tyler Lauren Mdirector
4359
0.0023%
$1.48M10
Szurek Paul E.President & CEO
242347
0.127%
$82.52M313
+9.09%
COLEMAN JAMES HSr. VP, Business Development
200397
0.105%
$68.24M10
<0.0001%
STOLL ROGER G PHDChief Executive Officer
100000
0.0524%
$34.05M70
<0.0001%
DRAKE PETER Fdirector
50000
0.0262%
$17.02M10
<0.0001%
STAPLE PETER DPresident & CEO
34878
0.0183%
$11.88M20
+13.64%
ALLNUTT ROBERTdirector
30000
0.0157%
$10.21M10
+9.77%
Tran Pierre VChief Medical Officer
30000
0.0157%
$10.21M10
<0.0001%
TOLLEFSON GARY Ddirector
28000
0.0147%
$9.53M10
<0.0001%
Tobin Dominic M.SVP, Operations
23892
0.0125%
$8.14M228
+21.22%
Dunn David W.SVP, Mergers and Acquisitions
19171
0.01%
$6.53M11
+19.95%
MESSINGER MARIA SChief Financial Officer
15000
0.0079%
$5.11M10
<0.0001%
Bair Christopher M.SVP, Sales and Leasing
11525
0.006%
$3.92M11
+4.6%
Price Chuck D.SVP, Information Technology
9556
0.005%
$3.25M10
+20.34%
Thompson John Daviddirector
8629
0.0045%
$2.94M11
+22.11%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

Cencora
(COR)
$1,022,434
25
4.69%
$64.98B

COR Institutional Investors: Active Positions

Increased Positions732+48.35%17M+9.02%
Decreased Positions648-42.8%18M-9.18%
New Positions216New2MNew
Sold Out Positions95Sold Out3MSold Out
Total Postitions1,598+5.55%192M-0.16%

COR Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vanguard Group Inc$7.93M12.06%23.4M+916,506+4.08%2025-09-30
Blackrock, Inc.$6.7M10.2%19.78M+1M+5.74%2025-09-30
State Street Corp$3.11M4.74%9.19M+782,911+9.31%2025-09-30
Price T Rowe Associates Inc /Md/$2.62M3.98%7.72M-70,668-0.91%2025-09-30
Walgreens Boots Alliance, Inc.$2.53M3.85%7.47M-3M-28.01%2025-06-30
Geode Capital Management, Llc$1.79M2.73%5.29M+502,812+10.5%2025-09-30
Jpmorgan Chase & Co$1.59M2.41%4.68M+771,198+19.74%2025-09-30
Boston Partners$1.53M2.32%4.51M+89,506+2.02%2025-09-30
Invesco Ltd.$1.36M2.07%4.01M-31,769-0.79%2025-09-30
Wellington Management Group Llp$1.35M2.05%3.97M+115,278+2.99%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.